Universe Pharmacy - חוב כולל להון UPC

Universe Pharmaceuticals is expanding its B2B presence by increasing the supply of Eastern medicines to pharmacy chains. However, rising raw material costs and strict quality control oversight are weighing on profitability. This price chart, which assists in the asset's baseline valuation, demonstrates a debt-to-equity ratio of 0.16. The company's revenues rely on stable demand from Chinese retirees for herbal preparations used in the therapy of chronic ailments.

Universe Pharmaceuticals optimizes costs by outsourcing logistics and raw material cultivation to external contractors, allowing the company to flexibly manage its operating cycle. By analyzing the company's debt-to-equity ratio, an investor assesses the proportion of borrowed funds within the balance sheet structure relative to equity, which determines the business's level of dependence on creditors and the issuer's overall financial stability.